VC
ASND icon

Vivo Capital’s Ascendis Pharma A/S ASND Stock Holding History

Vivo Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-146,025
Closed -$15.1M – 49
2022
Q3 		$15.1M Hold
146,025
– – 1.66% 17
2022
Q2 		$13.6M Sell
146,025
-296,477
-67% -$27.9M 1.36% 19
2022
Q1 		$51.9M Hold
442,502
– – 3.58% 7
2021
Q4 		$59.5M Sell
442,502
-318,104
-42% -$47.3M 3.59% 8
2021
Q3 		$121M Sell
760,606
-765,753
-50% -$105M 5.44% 6
2021
Q2 		$201M Sell
1,526,359
-137,883
-8% -$18.4M 8.69% 3
2021
Q1 		$214M Sell
1,664,242
-133,503
-7% -$20.3M 7.54% 4
2020
Q4 		$300M Hold
1,797,745
– – 13.38% 2
2020
Q3 		$277M Hold
1,797,745
– – 16.03% 1
2020
Q2 		$266M Sell
1,797,745
-205,402
-10% -$28.2M 19.06% 1
2020
Q1 		$226M Buy
+2,003,147
New +$260M 20.43% 1
2019
Q3 		– Sell
-2,060,135
Closed -$237M – 10
2019
Q2 		$237M Buy
2,060,135
+13,303
+0.6% +$1.59M 22.23% 1
2019
Q1 		$241M Sell
2,046,832
-120,000
-6% -$10.5M 24.02% 1
2018
Q4 		$136M Hold
2,166,832
– – 17.34% 1
2018
Q3 		$154M Hold
2,166,832
– – 15.48% 1
2018
Q2 		$144M Hold
2,166,832
– – 18.57% 1
2018
Q1 		$142M Buy
2,166,832
+400,000
+23% +$22.5M 20.07% 2
2017
Q4 		$70.8M Hold
1,766,832
– – 15.16% 1
2017
Q3 		$64M Hold
1,766,832
– – 12.94% 3
2017
Q2 		$49M Hold
1,766,832
– – 12.35% 3
2017
Q1 		$49.5M Hold
1,766,832
– – 14.55% 2
2016
Q4 		$35.8M Hold
1,766,832
– – 11.78% 2
2016
Q3 		$35.5M Hold
1,766,832
– – 11.07% 2
2016
Q2 		$23.4M Buy
1,766,832
+347,500
+24% +$5.36M 6.4% 5
2016
Q1 		$26.3M Buy
+1,419,332
New +$25.2M 6.6% 6

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vivo Capital's ASND Position: Q4 2022 in Review

Vivo Capital sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 146,025 shares — an estimated $15.1M sold.

Vivo Capital first reported a position in ASND in Q1 2016 and held it in 25 quarters. The position peaked at $300M in Q4 2020. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

  • Vivo Capital reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
  • Vivo Capital sold 146,025 Ascendis Pharma A/S shares in Q4 2022, an estimated $15.1M.
  • Vivo Capital first reported a position in Ascendis Pharma A/S in Q1 2016 and held it in 25 quarters.
  • Vivo Capital's Ascendis Pharma A/S position peaked at $300M in Q4 2020.
  • 187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.